The Efficacy of Vaccines to Prevent Infectious Diseases in the Elderly

  • Dietmar Herndler-Brandstetter
  • Beatrix Grubeck-Loebenstein
Part of the Medical Intelligence Unit book series (MIUN)


Infectious diseases still represent a major challenge to human progress and survival. Especially elderly persons are more frequently and severely affected by infectious diseases and they display distinct features with respect to clinical presentation and treatment. Although vaccinations are considered a vital medical procedure for preventing morbidity and mortality caused by infectious diseases, the protective effect of vaccinations is abrogated in elderly persons. This is due to a decline in the functions of the immune system referred to as immunosenescence. The first part of this chapter will therefore summarize the status quo of the efficacy of vaccines in preventing morbidity and mortality caused by typical infectious diseases in the elderly, such as influenza, pneumonia and tuberculosis. The second part will then elucidate the underlying age-related mechanisms which may contribute to the decreased efficacy of vaccines. Based on the complex mechanisms involved in immunosenescence, strategies will be outlined which may be succesfful in enhancing protective immune responses following vaccination in elderly persons.


Influenza Virus Herpes Zoster Elderly Person Severe Acute Respiratory Syndrome Influenza Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Anderson RN, Smith BL. Deaths: leading causes for 2002. Natl Vital Stat Rep 2005; 53(17):1–89.PubMedGoogle Scholar
  2. 2.
    Weiss RA, McMichael AJ. Social and environmental risk factors in the emergence of infectious diseases. nat Med 2004; 10(12 Suppl):S70–76.CrossRefGoogle Scholar
  3. 4.
    Fenner F. A successful eradication campaign. Global eradication of smallpox. Rev Infect Dis 1982; 4(5):916–930.PubMedGoogle Scholar
  4. 5.
    Pharmaceutical Research and Manufacturers of America, 2004 Survey: New Medicines in development for Infectious diseases, 2004.Google Scholar
  5. 6.
    Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis 2002; 2(11):659–666.PubMedCrossRefGoogle Scholar
  6. 7.
    barker WH, Mullooly JP. Pneumonia and influenza deaths during epidemics: implications for prevention. Arch Intern Med 1982; 142(1):85–89.PubMedCrossRefGoogle Scholar
  7. 8.
    Influenza and pneumococcal vaccination coverage among persons aged > or=65 years and persons aged 18–64 years with diabetes or asthma—United States, 2003. MMWR Morb Mortal Wkly Rep 2004; 53(43):1007–1012.Google Scholar
  8. 9.
    Gross PA, Hermogenes AW, Sacks HS et al. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995; 123(7):518–527.PubMedGoogle Scholar
  9. 10.
    Bouree P. Immunity and immunization in elderly. Pathol Biol (Paris) 2003; 51(10):581–585.Google Scholar
  10. 11.
    Nichol KL, Margolis KL, Wuorenma J et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331(12):778–784.PubMedCrossRefGoogle Scholar
  11. 12.
    Mullooly JP, Bennett MD, Hornbrook MC et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994; 121(12):947–952.PubMedGoogle Scholar
  12. 13.
    Ahmed AE, Nicholson KG, Nguyen-Van-Tam JS. Reduction in mortality associated with influenza vaccine during 1989–90 epidemic. Lancet 1995; 346(8975):591–595.PubMedCrossRefGoogle Scholar
  13. 14.
    Iob A, Brianti G, Zamparo E et al. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect 2005; 133(4):687–693.PubMedCrossRefGoogle Scholar
  14. 15.
    Gluck R, Mischler R, Finkel B et al. Immunogenicity of new virosome infuenza vaccine in elderly people. Lancet 1994; 344(8916):160–163.PubMedCrossRefGoogle Scholar
  15. 16.
    Conne P, Gauthey L, Vernet P et al. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 1997; 15(15):1675–1679.PubMedCrossRefGoogle Scholar
  16. 17.
    Ruf BR, Colberg K, Frick M et al. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 2004; 32(4):191–198PubMedCrossRefGoogle Scholar
  17. 18.
    de Bruijn IA, Nauta J, Cramer WC et al. Clinical experience with inactivated, virosomal influenza vaccine. Vaccine 2005; 23 Suppl 1:S39–49.CrossRefGoogle Scholar
  18. 19.
    Ruben FL. Inactivated influenza virus vaccines in children. Clin Infect Dis 2004; 38(5):678–688.PubMedCrossRefGoogle Scholar
  19. 20.
    Reichert TA, Sugaya N, Fedson DS et al. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001; 334(2):889–896.CrossRefGoogle Scholar
  20. 21.
    EARSS Annual Report, available at: Scholar
  21. 22.
    Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol 2004; 19(4):353–363.PubMedCrossRefGoogle Scholar
  22. 23.
    Wagner C, Popp W, Posch M et al. Impact of pneumococcal vaccination on morbidity and mortality of geriatric patients: a case-controlled study. Gerontology 2003; 49(4):246–250.PubMedCrossRefGoogle Scholar
  23. 24.
    Lexau CA, Lynfield R, Danila R et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. Jama. 2005; 294(16):2043–2051.PubMedCrossRefGoogle Scholar
  24. 25.
    Dutt AK, Stead WW. Tuberculosis. Clin Geriatr Med 1992; 8(4):761–775.PubMedGoogle Scholar
  25. 26.
    Rajagopalan S, Yoshikawa TT. Tuberculosis in the elderly. Z Gerontol Geriatr 2000; 33(5):374–380.PubMedCrossRefGoogle Scholar
  26. 27.
    WHO. AntiTB drug resistance in the world. Report no.2. Prevalence and trends. Geneva. Report No.: WHO/CDS/TB/2000.278. 2000.Google Scholar
  27. 28.
    Colditz GA, Brewer TF, Berkey CS et al. Efficacy of BCG vaccine in the prevention of tubereulosis. Meta-analysis of the published literature. Jama 1994; 271(9):698–702.PubMedCrossRefGoogle Scholar
  28. 29.
    McShane H. Coinfection with HIV and TB: double trouble. Int J STD AIDS 2005; 16(2):95–100; quiz 101.PubMedCrossRefGoogle Scholar
  29. 30.
    Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001; 19:93–129.PubMedCrossRefGoogle Scholar
  30. 31.
    Ragozzino MW, Melton LJ, 3rd, Kurland LT et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982; 61(5):310–316.Google Scholar
  31. 32.
    Arvin AM. Varicella-Zoster virus: pathogenesis, immunity and clinical management in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2000; 6(3):219–230.PubMedCrossRefGoogle Scholar
  32. 33.
    Mehta SK, Cohrs RJ, Forghani B et al. Stress-induced subclinical reactivation of varicella zoster virus in astronauts. J Med Virol 2004; 72(1):174–179.PubMedCrossRefGoogle Scholar
  33. 34.
    Arvin AM, Gershon AA. Live attenuated varicella vaccine. Annu Rev Microbiol 1996; 50:59–100.PubMedCrossRefGoogle Scholar
  34. 35.
    Weir E. Vaccination boosts adult immunity to varicella zoster virus. Cmaj 2005; 173(3):249.PubMedGoogle Scholar
  35. 36.
    Oxman MN, Levin MJ, Johnson GR et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352(22):2271–2284.PubMedCrossRefGoogle Scholar
  36. 37.
    Almanzar G, Schwaiger S, Jenewein B et al. Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J Virol 2005; 79(6):3675–3683.PubMedCrossRefGoogle Scholar
  37. 38.
    Pawelec G, Akbar A, Caruso C et al. Human immunosenescence: is it infectious? Immunol Rev 2005; 205:257–268.PubMedCrossRefGoogle Scholar
  38. 39.
    Ouyang Q, Wagner WM, Zheng W et al. Dysfunctional CMV-specific CD8+ T-cells accumulate in the elderly. Exp Gerontol 2004; 39(4):607–613.PubMedCrossRefGoogle Scholar
  39. 40.
    Holtappels R, Podlech J, Pahl-Seibert MF et al. Cytomegalovirus misleads its host by priming of CD8 T-cells specific for an epitope not presented in infected tissues. J Exp Med 2004; 199(1):131–136.PubMedCrossRefGoogle Scholar
  40. 41.
    Khan N, Shariff N, Cobbold M et al. Cytomegalovirus seropositivity drives the CD8 T-cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 2002; 169(4):1984–1992.PubMedGoogle Scholar
  41. 42.
    Franceschi C, Bonafe M, Valensin S et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000; 908:244–254.PubMedCrossRefGoogle Scholar
  42. 43.
    Saurwein-Teissl M, Lung TL, Marx F et al. Lack of antibody production following immunization in old age: association with CD8+CD28 T-cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol 2002; 168(11):5893–5899.PubMedGoogle Scholar
  43. 44.
    Riddell SR, Watanabe KS, Goodrich JM et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones. Science 1992; 257(5067):238–241.PubMedCrossRefGoogle Scholar
  44. 45.
    Cherry JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 2005; 115(5):1422–1427.PubMedCrossRefGoogle Scholar
  45. 46.
    Mertens PL, Stals FS, Schellekens JF et al. An epidemic of pertussis among elderly people in a religious institution in The Netherlands. Eur J Clin Microbiol Infect Dis 1999; 18(4):242–247.PubMedCrossRefGoogle Scholar
  46. 47.
    Steger MM, Maczek C, Berger P et al. Vaccination against tetanus in the elderly: do recommended vaccination strategies give sufficient protection. Lancet 1996; 348(9029):762.PubMedCrossRefGoogle Scholar
  47. 48.
    Grubeck-Loebenstein B, Berger P, Saurwein-Teissl M et al. No immunity for the elderly. Nat Med 1998; 4(8):870.PubMedCrossRefGoogle Scholar
  48. 49.
    Gergen PJ, McQuillan GM, Kiely M et al. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med 1995; 332(12):761–766.PubMedCrossRefGoogle Scholar
  49. 50.
    Gomez I, Marx F, Gould EA et al. T-cells from elderly persons respond to neoantigenic stimulation with an unimpaired IL-2 production and an enhanced differentiation into effector cells. Exp Gerontol 2004; 39(4):597–605.PubMedCrossRefGoogle Scholar
  50. 51.
    Suss J. Epidemiology and ecology of TBE relevant to the production of effective vaccines. Vaccine 2003; 21 Suppl 1:S19–35.CrossRefGoogle Scholar
  51. 52.
    Kunz C. TBE vaccination and the Austrian experience. Vaccine. 2003; 21 Suppl 1:S50–55.CrossRefGoogle Scholar
  52. 53.
    Rendi-Wagner P, Kundi M, Zent O et al. Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation. Vaccine 2004; 23(4):427–434.PubMedCrossRefGoogle Scholar
  53. 54.
    Steffen R, Kane MA, Shapiro CN et al. Epidemiology and prevention of hepatitis A in travelers. Jama 1994;272(11):885–889.PubMedCrossRefGoogle Scholar
  54. 55.
    Steffen R. Hepatitis A and hepatitis B: risks compared with other vaccine preventable diseases and immunization recommendations. Vaccine 1993; 11(5):518–520.PubMedCrossRefGoogle Scholar
  55. 56.
    Joines RW, Blatter M, Abraham B et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. Vaccine 2001; 19(32):4710–4719.PubMedCrossRefGoogle Scholar
  56. 57.
    Hopperus Buma AP, van Doornum GJ, Veltink RL et al. Immunogenicity of an inactivated hepatitis A vaccine in Dutch United Nations troops. Vaccine 1997; 15(12–13):1413–1417.PubMedCrossRefGoogle Scholar
  57. 58.
    Wolters B, Junge U, Dziuba S et al. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine 2003; 21(25–26):3623–3628.PubMedCrossRefGoogle Scholar
  58. 59.
    Reuman PD, Kubilis P, Hurni W et al. The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults. Vaccine 1997; 15(10):1157–1161.PubMedCrossRefGoogle Scholar
  59. 60.
    WHO. District guidelines for yellow fever surveillance. Geneva, Switzerland. Available at http://www. 1998.Google Scholar
  60. 61.
    Poland JD, Calisher CH, Monath TP et al. Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 1981; 59(6):895–900.PubMedGoogle Scholar
  61. 62.
    Martin M, Weld LH, Tsai TF et al. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 2001; 7(6):945–951.PubMedCrossRefGoogle Scholar
  62. 63.
    Aspinall R and rew D. Thymic involution in aging. J Clin Immunol 2000; 20(4):250–256.PubMedCrossRefGoogle Scholar
  63. 64.
    George AJ, Ritter MA. Thymic involution with ageing: obsolescence or good housekeeping? Immunol Today 1996; 17(6):267–272.PubMedCrossRefGoogle Scholar
  64. 65.
    Lazuardi L, Jenewein B, Wolf AM et al. Age-related loss of naive T-cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology 2005; 114(1):37–43.PubMedCrossRefGoogle Scholar
  65. 66.
    Zanni F, Vescovini R, Biasini C et al. Marked increase with age of type 1 cytokines within memory and effector/cytotoxic CD8+ T-cells in humans: a contribution to understand the relationship between inflammation and immunosenescence. Exp Gerontol 2003; 38(9):981–987.PubMedCrossRefGoogle Scholar
  66. 67.
    Grubeck-Loebenstein B, Wick G. The aging of the immune system. Adv Immunol 2002; 80:243–284.PubMedCrossRefGoogle Scholar
  67. 68.
    Effros RB, Cai Z, Linton PJ. CD8 T-cells and aging. Crit Rev Immunol 2003; 23(1–2):45–64.PubMedCrossRefGoogle Scholar
  68. 69.
    Goronzy JJ, Fulbright JW, Crowson CS et al. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol 2001; 75(24):12182–12187.PubMedCrossRefGoogle Scholar
  69. 70.
    Shoenfeld Y, Sherer Y, Harats D. Artherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol 2001; 22(6):293–295.PubMedCrossRefGoogle Scholar
  70. 71.
    Weyand CM, Fulbright JW, Goronzy JJ. Immunosenescence, autoimmunity and rheumatoid arthritis. Exp Gerontol 2003; 38(8):833–841.PubMedCrossRefGoogle Scholar
  71. 72.
    Blasko I, Grubeck-Loebenstein B. Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer’s disease. Drugs Aging 2003; 20(2):101–113.PubMedCrossRefGoogle Scholar
  72. 73.
    Blasko I, Stampfer-Kountchev M, Robatscher P et al. How chronic inflammation can affect the brain and support the development of Alzheimer’s disease in old age: the role of microglia and astrocytes. Aging Cell 2004; 3(4):169–176.PubMedCrossRefGoogle Scholar
  73. 74.
    Labrie JE, 3rd, Sah AP, Allman DM et al. Bone marrow microenvironmental changes underlie reduced RAG-mediated recombination and B-cell generation in aged mice. J Exp Med 2004; 200(4):411–423.PubMedCrossRefGoogle Scholar
  74. 75.
    Weksler ME, Szabo P. The effect of age on the B-cell repertoire. J Clin Immunol 2000; 20(4):240–249.PubMedCrossRefGoogle Scholar
  75. 76.
    Johnson SA, Cambier JC. Ageing, autoimmunity and arthritis: senescence of the B-cell compartment-implications for humoral immunity. Arthritis Res Ther 2004; 6(4):131–139.PubMedCrossRefGoogle Scholar
  76. 77.
    Aydar Y, Balogh P, Tew JG et al. Age-related depression of FDC accessory functions and CD21 ligand-mediated repair of costimulation. Eur J Immunol 2002; 32(10):2817–2826.PubMedCrossRefGoogle Scholar
  77. 78.
    Colonna-Romano G, Bulati M, Aquino A et al. B-cells in the aged: CD27, CD5 and CD40 expression. Mech Ageing Dev 2003; 124(4):389–393.PubMedCrossRefGoogle Scholar
  78. 79.
    McGlauchlen KS, Vogel LA. Ineffective humoral immunity in the elderly. Microbes Infect 2003; 5(13):1279–1284.PubMedCrossRefGoogle Scholar
  79. 80.
    Levine MM, Sztein MB. Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol 2004; 5(5):460–464.PubMedCrossRefGoogle Scholar
  80. 81.
    Kenney RT, Edelman R. Survey of human-use adjuvants. Expert Rev Vaccines 2003; 2(2):167–188.PubMedCrossRefGoogle Scholar
  81. 82.
    Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005; 11(4 Suppl):S63–68.CrossRefGoogle Scholar
  82. 83.
    Barouch DH, Santra S, Steenbeke TD et al. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol 1998; 161(4):1875–1882.PubMedGoogle Scholar
  83. 84.
    Kutzler MA, Robinson TM, Chattergoon MA et al. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T-cells that are partially independent of CD4 T-cell help. J Immunol 2005; 175(1):112–123.PubMedGoogle Scholar
  84. 85.
    Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype and affinity of the antigen-specific CD8 T-cell response. J Immunol 2005; 175(4):2261–2269.PubMedGoogle Scholar
  85. 86.
    Melchionda F, Fry TJ, Milliron MJ et al. Adjuvant IL7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest 2005; 115(5):1177–1187.PubMedGoogle Scholar
  86. 87.
    Hainz U, Jenewein B, Asch E et al. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine 2005; 23(25):3232–3235.PubMedCrossRefGoogle Scholar
  87. 88.
    Herndler-Brandstetter D, Cioca DP, Grubeck-Loebenstein B. Immunizations in the elderly: do they live up to their promise. Wien Med Wochenschr 2006; 156(5–6):130–141.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2007

Authors and Affiliations

  • Dietmar Herndler-Brandstetter
    • 1
  • Beatrix Grubeck-Loebenstein
    • 1
  1. 1.Institute for Biomedical Aging ResearchAustrian Academy of SciencesInnsbruckAustria

Personalised recommendations